Pregnancy induces a modulation of the cAMP phosphodiesterase 4- conformers ratio in human myometrium: Consequences for the utero-relaxant effect of PDE4-selective inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 817-823

  Méhats, Céline ^a   Tanguy, Gisèle ^a   Paris, Brigitte ^a   Robert, Brigitte ^a   Pernin, Nadja ^b   Ferré, Françoise ^a   Leroy, Marie Josèphe ^a  

^a INSERM   (France)

^b Univ René Descartes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP PHOSPHODIESTERASE; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROLIPRAM;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME CONFORMATION; HUMAN; HUMAN TISSUE; MYOMETRIUM; PREGNANCY; PRIORITY JOURNAL; UTERUS RELAXATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BENZAMIDES; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOBLOTTING; MUSCLE RELAXATION; MYOMETRIUM; PHOSPHODIESTERASE INHIBITORS; PREGNANCY; PYRIDINES; ROLIPRAM; UTERINE CONTRACTION;

EID: 0343484986     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ashton MJ, Cook DC, Fenton G, Karlsson J-A, Palfreyman MN, Raeburn D, Ratcliffe AJ, Souness JE, Thurairatnam S and Vicker N (1994) Selective type IV phosphodiesterase inhibitors as anti-asthmatic agents. The syntheses and biological activities of 3-cyclopentyloxy-4-methoxybenzamides and analogues. J Med Chem 37: 1696-1703.
2. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB and Torphy TJ (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands. Corellation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273:1396-1402.
3. Bolger GE, Erdogan S, Jones RJ, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C and Houslay MD (1997) Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J 328:539-548.
4. Casey ML, Cox SM, Word RA and MacDonald PC (1990) Cytokines and infection-induced preterm labour. Reprod Fertil Dev 2:499-509.
5. Conti M, Nemoz G, Sette O and Vicini E (1995) Recent progress in understanding the hormonal regulation of phophodiesterases. Endocrine Rev 16:370-389.
6. Dent G and Giembyez MA (1996) Interaction of PDE4 inhibitors with enzymes and cell functions, in Phosphodiesterase Inhibitors (Schudt C, Dent G and Rabe KF eds) pp 111-126, Academic Press. London.
7. Esskyan DM, Huang SK, Ondem BJ, Kagey-Sobotka A and Lichtenstein LM (1994) Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 153:3408-3416.
8. Heaslip RJ and Evans DY (1995) Emutic central nervous system, and pulmonary activities of rolipram in the Dog. Eur J. Pharmacol 286:281-290.
9. Housley MD, Sullivan M and Bolger GB (1998) The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular target-ing, regulation, and selective inhibition by compounds exerting anti-inflammatory and anti-depressant actions. Adv Pharmacol 44:225-342.
10. Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger GB and Housley MD (1996) The human cyclic, AMP-specific phosphodiesterase PDE-46 (HSPDEsA4B) expressed in transfected COS7 cells occurs as both particulate and cytosotic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344.
11. Iona S, Coumo M, Bashnik T, Nuro F, Sette C, Hess M, Shelton ER and Conti M (1998) Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases. Identification and differential expression of immunologically distinct forms in the rat brain. Mol Pharmacol 53:23-32.
12. Jacobitz S, McLaughlin MM, Livi GP, Burman M and Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements, for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899.
13. Kincaid RL and Mariganiello VC (1988) Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrates. Methods Enzymol 159:457-470.
14. Leroy M-J, Blot P and Ferré F (1987) Characterization by DEAE-cellulose chromatography of a single molecular form of cyclic nucleotide phosphodiesterase in the myometrium of non-pregnant women. Gynecol Obstet Invest 24:190-199.
15. Leroy M-J, Cedrin I, Breuiller M, Giovagrandi Y and Ferré F (1989) Correlation between affective inhibition of the cyclic nucleotide phosphodiesterases and the contractile activity in human pregnant myometrium near term. Biochem Pharmacol 38:9-13.
16. Leroy M-J, Lugnier C, Merezak J, Tanguy G, Olivier S, Le Bec A and Ferré F (1994) Isolation and characterization of the rolipram-sensitive cyclic AMP-specific phosphodiesterase (type IV PDE) in human term myometrium. Cell Signal 6:405-412.
17. Leroy M-J, Méhats C, Duc-Goiran P, Tanguy G, Robert B, Dallot E, Mignot TM, Grange G and Ferré F (1999) Effect of pregnancy on PDE4 cAMP-specific phosphodiesterase messenger ribonucleic acid expression in human myometrium. Cell Signal 11:31-37.
18. Leroy M-J, Pichard A-L, Cabrol D and Ferré F (1985) Cyclic 3′:5′-nucleotide phosphodiesterase in human myometrium at the end of pregnancy: Partial purification and characterization of the different soluble isoenzymes. Gynecol Obstet Invest 20:27-36.
19. Ma D, Wu P, Egan RW, Billah MM and Wang P (1999) Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 55:50-57.
20. Méhats C, Tanguy G, Dallot E, Robert B, Rebourcet R, Ferrê F and Leroy M-J (1999) Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3′, 5′-monophosphate (cAMP)-specific phosphodiesterase variants by elevated cAMP content in human myometrial cells in culture. Endocrinology 140:3228-3237.
21. Owens RJ, Lumb S, Rees-Milton K, Russel A, Baldock D, Lang V, Crabbe T, Ballesteros M and Perry MJ (1997) Molecular cloning and expression of a human phosphodiesterase 4C. Cell Signal 9:575-585.
22. Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lumb S, Huang Z, Howat D, Allen R, Merriman M, Walls J, Daniel T, Hughes B, Laliberte F, Higgs GA and Owens RJ (1998) CDP840: A novel inhibitor of PDE-4. Cell Biochem Biophys 29:113-132.
23. Radetsky P (1994) Stopping premature births before it's too late. Science (Wash DC) 266:1486-1488.
24. Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, Webber SE and Karlsson J-A (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113:1423-1431.
25. Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC, Kadwell SH, Hoffman CR and Luther MA (1997) Human recombinant phosphodiesterase 4B2B binds (R)-Rolipram at a single site with two affinities. Biochemistry 36:14250-14261.
26. Schneider HH, Schmiechen R, Brezinski M and Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115.
27. Silver PJ and Krafte DS (1996) Pharmacological regulation of smooth muscle by ion channels, kinases, and cyclic nucleotides, in Biochemistry of Smooth Muscle Contraction (Barany M ed) pp 367-376, Academic Press, San Diego.
28. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN and Karlsson J-A (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer. Br J Pharmacol 118:649-658.
29. Souness JE, Malsen C, Webber S, Foster M, Raeburn D, Palfreyman MN, Ashton MJ and Karlsson J-A (1995) Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic cAMP-phosphodiesterase: Comparison with rolipram. Br J Pharmacol 115:39-46.
30. Souness JE and Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227-236.
31. Teixeira MM, Gristwood RW, Cooper N and Hellewell PG (1997) Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol Sci 18:164-170.
32. Thomson AJ, Telfer JF, Young A, Campbell S, Stewart CJR, Cameron IT, Greer IA and Norman JE (1999) Leukocytes infiltrate the myometrium during human parturition: Further evidence that labour is an inflammatory process. Hum Reprod 14:223-236.
33. Torphy TJ (1998) Phosphodiesterase isoenzymes-molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 157:351-370.
34. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR and Livi GP (1992) Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267:1798-1804.
35. Torphy TJ, Zhou HL, Foley JJ, Sarau HM, Manning CD and Barnette MS (1995) Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. J Biol Chem 270:23598-23604.
36. Wang P, Wu P, Ohleth KM, Egan RW and Billah MM (1999) Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56:170-174.